• Neuron specific gene therapy that delivers Caveolin-1 to promote neuronal plasticity & synaptic communication to facilitate neuronal repair
• Proof of Concept: SynCav1 treatment demonstrated significant increases in dendritic and axonal growth in human neurons derived from induced pluripotent stem cells (iPSCs)
SynCav1 induces neuronal specific regenerative processes, facilitating neuronal repair and slowing neuronal degeneration
Uses a neuron-specific synapsin promoter to drive Caveolin-1 over-expression in neurons
Transgene expression increases neuroplasticity, resulting in improved motor function, longevity, memory, cognition and function in ALS mice and Alzheimer's Disease mice
Delivered non-systemically using Adeno-Associated Virus (AAV)
Gene expression platform for multiple CNS and neurodegenerative diseases
Validated animal data lead to long term diversified risk
Transition from research to IND-enabling studies for rapid commercialization
Emphasis on protecting intellectual property and shareholder value
Significant potential for non-dilutive financing and partnering activities
Strategic financing, exit and liquidity options Multiple strategic partnerships
Exclusive license from UCSD
2 issued patents with extensive claims & FTO
Non-Provisional PCT (2020 actionable date)
Gavrilovich, Dodd & Lindsey LLP (IP counsel)
Tucker Ellis, LLP (Corporate counsel)
UC San Diego School of Medicine researchers previously found that boosting a membrane protein called caveolin-1 specifically in neurons (dubbed "SynCav1") improved memory in older mice and enhanced their functional neuroplasticity — the ability to adapt to new situations and form new memories.
Biotech company CavoGene LifeSciences has licensed a novel investigational gene therapy from the University of California San Diego and brought the technology across the country to Cleveland, where the six-month-old firm will be headquartered.
GLEN BURNIE, Md., Oct. 23, 2018 /PRNewswire/ -- CavoGene LifeSciences has announced that it has licensed a novel investigational gene therapy for patients with neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), traumatic brain and spinal cord injury, and age-related cognitive decline. Currently, there is a large unmet medical need for these life-threatening conditions.
6958 Aviation Blvd., Suite H
Glen Burnie, MD 21061